DavidMMargolisMD

Infectious Disease • Chapel Hill, NC

HIV/AIDS Medicine

Professor, Medicine, University of North Carolina at Chapel Hill School of Medicine

Join to view full profile

Dr. Margolis is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Margolis' full profile

Already have an account?

Office
101 Manning Dr
Chapel Hill, NC 27599
Phone+1 984-974-7198

Education & Training

University of Massachusetts Medical SchoolPost-Doctoral Fellowship, 1991 - 1994
National Institutes of Health Clinical CenterFellowship, Infectious Disease, 1988 - 1991
Tufts Medical CenterResidency, Internal Medicine, 1985 - 1988
Tufts University School of MedicineClass of 1985

Certifications & Licensure

NC State Medical License 2005 - 2025
TX State Medical License 2001 - 2006
MD State Medical License 1989 - 2001
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Infectious Disease

Awards, Honors, & Recognition

Fellow AAAS, 2022
Elected Member Association of American Physicians, 2019
Elected Member The American Society for Clinical Investigation, 2005
Fellow Infectious Diseases Society of America, 1996
Fellow American College of Physicians, 1994
Join now to see all

Clinical Trials

Mycophenolate Mofetil and Abacavir Treatment in HIV Patients With Failed Anti-HIV Treatment
Withdrawn
Phase 2
A Study of DAPD Alone Versus DAPD Plus MMF for Treatment of HIV Infection
Completed
Phase 2
Study of Valproic Acid to Treat HIV Infected Adults Start of enrollment: 2006 Jun 01
Terminated
Phase 1
MK-0518 Intensification And HDAC Inhibition In Depletion Of Resting CD4+ T Cell HIV Infection Start of enrollment: 2007 Apr 01
Terminated
Phase 2
HIV Viremia and Persistence in Acutely HIV-Infected Patients Treated With Darunavir/Ritonavir and Etravirine Start of enrollment: 2009 Mar 01
Terminated
Phase 4
The Effect of Vorinostat on HIV RNA Expression in the Resting CD4+ T Cells of HIV+ Pts on Stable ART Start of enrollment: 2011 Feb 01
Completed
Phase 1, Phase 2
Safety and Effect on HIV Transcription of Vorinostat in Patients Receiving Suppressive Combination Anti-retroviral Therapy Start of enrollment: 2011 May 01
Unknown status
Phase 2
A Phase I Study to Evaluate the Immunologic Response and Virologic Impact of AGS-004 Start of enrollment: 2014 Mar 01
Completed
Phase 1
Phase I Study of HIV 1 Antigen Expanded Specific T Cell Therapy Start of enrollment: 2015 Apr 07
Completed
Phase 1
Pilot Trial of the Effect of Vorinostat and AGS-004 on Persistent HIV-1 Infection Start of enrollment: 2016 Mar 01
Terminated
Phase 1
Join now to see all

Publications & Presentations

PubMed

1 citations
BET degraders reveal BRD4 disruption of 7SK and P-TEFb is critical for effective reactivation of latent HIV in CD4+ T-cells.
Anne-Marie W Turner, Frances M Bashore, Shane D Falcinelli, Joshua A Fox, Alana L Keller
Journal of Virology. 2025-03-11
The persistent pool of HIV-1-infected cells is formed episodically during untreated infection.
Olivia D Council, Lynn Tyers, Matthew Moeser, Amy Sondgeroth, Ean Spielvogel
Journal of Virology. 2025-02-25
NF-κB dependent gene expression and plasma IL-1β, TNFα and GCSF drive transcriptomic diversity and CD4:CD8 ratio in people with HIV on ART.
Yingfan Wang, German G Gornalusse, David A Siegel, Alton Barbehenn, Rebecca Hoh
Biorxiv. 2025-02-14

Journal Articles

The Control of HIV After Antiretroviral Medication Pause (CHAMP) Study: Post-Treatment Controllers Identified from 14 Clinical Studies
Elizabeth Connick, Michael C Sneller, Jonathan Z Li, Paul Volberding, Daniel R Kuritzkes, Robert T Schooley, David Margolis, Daniel Skiest, John W Mellors, Ronald Mits..., The Journal of Infectious Diseases

Press Mentions

Brii Biosciences Announces Positive Data Demonstrating Its Long-Acting COVID-19 Neutralizing Antibody Therapy, Amubarvimab/Romlusevimab Combination, Retains Neutralizing Activity Against Live Omicron Virus BA.4/5 and BA.2.12.1 SubvariantsJuly 27th, 2022
Brii Bio Announces Positive Data Demonstrating Its Long-Acting COVID-19 Neutralizing Antibody Therapy, Amubarvimab/Romlusevimab Combination, Retains Neutralizing Activity Against Omicron BA.2 SubvariantMay 9th, 2022
Why COVID-19 Cases May Continue to Decline in the United StatesApril 7th, 2022
Join now to see all